To improve psoriatic arthritis outcomes, address common comorbiditiesMarch 12, 2021Psoriatic ArthritisPsoriasis
Anybody for a nanobody? Novel psoriasis therapy impresses in phase 2bFebruary 10, 2021PsoriasisPsoriatic Arthritis
Synovial, skin gene expression differences may explain PsA treatment responsesDecember 11, 2020Psoriatic ArthritisPsoriasis
The case for anti–IL-17 agents as first-line biologics in psoriatic arthritisNovember 30, 2020Psoriatic ArthritisPsoriasis
Guselkumab improvements for psoriatic arthritis persist through 1 yearOctober 15, 2020Psoriatic Arthritis
Psoriasis, PsA, and pregnancy: Tailoring treatment with increasing dataSeptember 2, 2020PsoriasisPsoriatic Arthritis
Doctors hesitated to embrace biosimilar infliximab in first 2 yearsJuly 20, 2020Psoriatic ArthritisPsoriasis
Clinicians address psoriatic disease risk in the era of COVID-19July 17, 2020PsoriasisPsoriatic Arthritis
PASDAS beats DAS28 in measuring psoriatic arthritis treat-to-target successJuly 14, 2020Psoriatic Arthritis
Entheseal lesions, bone density linked with incident PsA in psoriasis patientsJune 11, 2020Psoriatic Arthritis
